Skip to content
The Policy VaultThe Policy Vault

Increlex (mecasermin)Medica

Growth Hormone Gene Deletion with neutralizing antibodies to growth hormone

Initial criteria

  • Patient is ≥ 2 years of age
  • The epiphyses are open
  • Patient has developed neutralizing antibodies to growth hormone
  • Patient will not be receiving concurrent treatment with growth hormone
  • Medication is prescribed by or in consultation with a pediatric endocrinologist

Reauthorization criteria

  • Patient’s height has increased by ≥ 2 cm/year in the most recent year
  • The epiphyses are open
  • Patient has developed neutralizing antibodies to growth hormone
  • Patient will not be receiving concurrent treatment with growth hormone

Approval duration

1 year